环球印务(002799) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥676,970,746.02, representing a 53.10% increase compared to ¥442,174,573.32 in the same period last year[7] - The net profit attributable to shareholders for Q1 2021 was ¥30,036,045.48, up 53.11% from ¥19,617,159.88 in the previous year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥25,981,142.63, reflecting a 43.54% increase from ¥18,099,941.84 year-on-year[7] - The basic earnings per share for Q1 2021 was ¥0.17, a 54.55% increase compared to ¥0.11 in the same period last year[7] - The total comprehensive income for the period was CNY 36,354,428.69, compared to CNY 24,479,212.66 in the prior year, marking a 48.6% increase[45] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,546,659,919.62, an increase of 3.14% from ¥1,499,501,682.56 at the end of the previous year[7] - The net assets attributable to shareholders at the end of the reporting period were ¥696,476,442.70, up 4.01% from ¥669,611,645.99 at the end of the previous year[7] - The company's total liabilities stood at CNY 777,526,659.43, up from CNY 752,787,414.95, indicating a rise in financial obligations[38] - The company's long-term equity investments increased from RMB 85.04 million to RMB 110.58 million during the same period[36] Cash Flow - The net cash flow from operating activities for Q1 2021 was -¥52,731,812.25, an improvement of 19.21% compared to -¥65,272,178.49 in the same period last year[7] - Operating cash inflow for the first quarter was CNY 92,432,700.17, an increase of 10.5% compared to CNY 83,798,671.94 in the previous period[55] - Operating cash outflow totaled CNY 96,486,471.76, down 36% from CNY 150,759,491.26 in the previous period[56] - The ending cash and cash equivalents balance was CNY 94,738,722.39, down from CNY 193,594,280.27 in the previous period[56] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,471[10] - The largest shareholder, Shaanxi Pharmaceutical Holdings Group Co., Ltd., holds 46.25% of the shares, totaling 83,250,000 shares[10] Research and Development - Research and development expenses surged by 311.80% to CNY 24,341,072.20, indicating a significant increase in investment in R&D activities[14] - Research and development expenses for the quarter were CNY 3,536,106.36, up from CNY 3,130,631.02, indicating a focus on innovation[48] Investments and Subsidiaries - The company completed a capital increase for its subsidiary, reducing its ownership from 70% to 49%, resulting in the subsidiary no longer being included in the consolidated financial statements[16] - The company established a wholly-owned subsidiary with a registered capital of CNY 50 million to support its strategic development and expansion plans[20] - The company signed an investment cooperation framework agreement to build an industrial park for pharmaceutical packaging and smart manufacturing in the Xi'an Xixian New Area[21] - The company signed an investment agreement to build an industrial park for green packaging and intelligent manufacturing in the Xixian New Area[22] Operational Costs - The company's gross profit margin improved, with operating costs rising by 52.38% to CNY 584,918,546.37, reflecting the increase in sales[14] - Total operating costs amounted to CNY 641,528,136.70, compared to CNY 415,316,153.16 in the prior period, reflecting a rise in operational expenses[44] Future Outlook - The company anticipates potential losses or significant changes in net profit for the first half of 2021 compared to the same period last year[27]